Ptc Therapeutics Inc. (PTCT)
PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ron Aldridge – Senior Director of Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Kylie O'Keefe - Chief Commercial Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph – J.P. Morgan Kelly Shi – Jefferies Samantha Corwin - William Blair Brian Abraham - RBC Capital Markets Joseph Thome - TD Cowen Jeff Hung - Morgan Stanley Gena Wang – Barclays David Lebowitz – Citi Joseph Schwartz - Leerink Partners Operator Good day and thank you for standing by.
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $2.66 per share a year ago.
Unlocking Q2 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of PTC Therapeutics (PTCT) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTCT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into PTC Therapeutics, Inc and Encourages Investors to Contact the Firm Today!
NEW YORK CITY, NY / ACCESSWIRE / July 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
PTCT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into PTC Therapeutics, Inc and Encourages Investors to Contact the Firm Today!
NEW YORK CITY, NY / ACCESSWIRE / July 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into PTC Therapeutics, Inc and Encourages Investors to Contact the Firm Today!
NEW YORK CITY, NY / ACCESSWIRE / July 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into PTC Therapeutics, Inc and Encourages Shareholders to Contact the Firm Today!
NEW YORK CITY, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds PTC Therapeutics, Inc Shareholders to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
PTCT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
PTCT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
